Doses - VINCRISTINE SULFATE
For more information, refer to the protocol references found in the appendix or otherprotocols found in numerous references, including: Handbook of Small Animal Practice (Ogilvie1988), (Cotter 1988), (Stann 1988a); Handbook of Small Animal Therapeutics (Rosenthal 1985);
Current Veterinary Therapy X: Small Animal Practice (Helfand 1989), (Matus 1989); and Textbook of Veterinary Internal Medicine, 3rd Edition (Couto 1989a).Dogs:
For neoplastic diseases (usually used in combination protocols with other drugs):
a) 0.5 - 0.75 mg/m2 IV every 7-14 days (O'Keefe and Harris 1990)
b) 0.5 mg/m2 every 7-14 days. (Coppoc 1988)
c) 0.5 mg/m2 IV weekly. (MacEwen and Rosenthal 1989)
d) For transmissible venereal tumor: 0.025 mg/kg (maximum dose 1 mg) IV once weekly.
Generally requires 3-6 weeks of therapy. Usually tumor regression noted within 2weeks of initial treatment. (Herron 1988)
e) For transmissible venereal tumor: 0.5 mg/m2 (maximum dose 1 mg) IV every 7 daysuntil there is no evidence of disease. Generally requires 4-6 weeks of therapy.(Rosenthal 1985)
For immune-mediated thrombocytopenia:
a) If corticosteroids alone are ineffective, may use instead or add: vincristine 0.010 - 0.025mg/kg IV at minimum of 7-10 day intervals. Alternatively, may use azathioprine, orcyclophosphamide. (Young 1988)
b) Used only when other therapies are ineffective and bone marrow aspirate demonstratesadequate megakaryocytopoiesis: 0.02 mg/kg IV once weekly. (Feldman 1989)
c) 0.010 - 0.025 mg/kg IV (maximum dose 1.5 mg) once every 4-7 days. (Hurvitz and Johnessee 1985)Cats:
For neoplastic diseases (usually used in combination protocols with other drugs):
a) 0.5 - 0.75 mg/m2 IV once a week. (Couto 1989b)
Monitoring Parameters -1. Efficacy (tumor burden reduction or platelet count); 2. Toxicity: a) Peripheral neuropathicclinical symptoms; b) Complete blood counts with platelets; c) Liver function tests prior totherapy and repeated if necessary; d) Serum uric acid
Client Information - Clients must be briefed on the possibilities of severe toxicity developingfrom this drug, including drug-related mortality. Clients should contact the veterinarian should thepatient exhibit any symptoms of profound depression, abnormal bleeding (including bloodydiarrhea) and/or bruising, severe constipation, or severe peripheral neuropathic symptoms.
Dosage Forms/Preparations/FDA Approval Status/Withholding Times - Veterinary-Approved Products: None
Oncovin® (Lilly), Vincasar PFS® (Adria), generic; (Rx)
Current Veterinary Therapy X: Small Animal Practice (Helfand 1989), (Matus 1989); and Textbook of Veterinary Internal Medicine, 3rd Edition (Couto 1989a).
Dogs: 
For neoplastic diseases (usually used in combination protocols with other drugs): a) 0.5 - 0.75 mg/m2 IV every 7-14 days (O'Keefe and Harris 1990)
b) 0.5 mg/m2 every 7-14 days. (Coppoc 1988)
c) 0.5 mg/m2 IV weekly. (MacEwen and Rosenthal 1989)
d) For transmissible venereal tumor: 0.025 mg/kg (maximum dose 1 mg) IV once weekly.
Generally requires 3-6 weeks of therapy. Usually tumor regression noted within 2weeks of initial treatment. (Herron 1988)
e) For transmissible venereal tumor: 0.5 mg/m2 (maximum dose 1 mg) IV every 7 daysuntil there is no evidence of disease. Generally requires 4-6 weeks of therapy.(Rosenthal 1985)
For immune-mediated thrombocytopenia:
a) If corticosteroids alone are ineffective, may use instead or add: vincristine 0.010 - 0.025mg/kg IV at minimum of 7-10 day intervals. Alternatively, may use azathioprine, orcyclophosphamide. (Young 1988)
b) Used only when other therapies are ineffective and bone marrow aspirate demonstratesadequate megakaryocytopoiesis: 0.02 mg/kg IV once weekly. (Feldman 1989)
c) 0.010 - 0.025 mg/kg IV (maximum dose 1.5 mg) once every 4-7 days. (Hurvitz and Johnessee 1985)
Cats: 
For neoplastic diseases (usually used in combination protocols with other drugs): a) 0.5 - 0.75 mg/m2 IV once a week. (Couto 1989b)
Monitoring Parameters -1. Efficacy (tumor burden reduction or platelet count); 2. Toxicity: a) Peripheral neuropathicclinical symptoms; b) Complete blood counts with platelets; c) Liver function tests prior totherapy and repeated if necessary; d) Serum uric acid
Client Information - Clients must be briefed on the possibilities of severe toxicity developingfrom this drug, including drug-related mortality. Clients should contact the veterinarian should thepatient exhibit any symptoms of profound depression, abnormal bleeding (including bloodydiarrhea) and/or bruising, severe constipation, or severe peripheral neuropathic symptoms.
Dosage Forms/Preparations/FDA Approval Status/Withholding Times - Veterinary-Approved Products: None
Human-Approved Products:
Vincristine Sulfate Injection 1 mg/ml in 1 ml, 2 ml and 5 ml vials & 1 & 2 ml Hyporets;Oncovin® (Lilly), Vincasar PFS® (Adria), generic; (Rx)